Andrew Lam

Bio:

Andrew Lam is Managing Director, Head of Biotech Private Equity at Ally Bridge Group, a leading global life science-dedicated investment group, where he leads private equity therapeutics investments including CG Oncology, ProfoundBio, RayzeBio and Sonoma Biotherapeutics. Dr. Lam has over 20 years of biopharma-focused experience across industry, equity research and investment banking. He joined Ally Bridge Group in 2021 from Intercept Pharmaceuticals, where he was Senior Director of Business Development. Prior to joining Intercept, Dr. Lam served as Vice President of Healthcare Investment Banking at Jefferies, where he completed over 30 biopharma financing and M&A transactions, and as an equity research associate at BMO Capital and Canaccord Genuity, where he covered biotech. Before his time on Wall Street, Dr. Lam spent a decade in medical affairs at several biotech companies including Celgene and Shire. He holds a PharmD from Long Island University and an MBA from Drexel University.